Due to a lack of publicly available data, understanding what products medical cannabis patients use for various conditions has mostly come from survey responses. In a new study, USC Schaeffer Center researchers established a clearer picture by analyzing point-of-sale data from nearly 17,000 patients who made more than 80,000 purchases as part of the New York state medical cannabis program.
The researchers found considerable variation in the products chosen for most medical conditions, and high variability in labeled doses of THC.
“While the medical cannabis market is not new, there is still relatively little research on patient purchasing behavior,” says Alexandra Kritikos, a postdoctoral research fellow in the USC Schaeffer Center and the USC Institute for Addiction Science. “Unfortunately, our analysis suggests that patients may not be getting consistent guidance from clinicians and pharmacists and, in many disease areas, there seems to be a lack of clear clinical data on appropriate dosing.”
2 responses to “Study shows patient preference for medical cannabis products in absence of clinical guidelines”
It must be difficult to design studies for cannabis, or there may be little monetary rewards for drug companies to do so. I hope the science catches up with the benefits and downsides of use.
LikeLiked by 1 person
It’s early times.